To the best of our knowledge, only a few pediatric studies have evaluated the discriminative capability of FGF-21 based on its sensitivity and specificity for NAFLD (27, 29), and none of the pediatric studies have combined FGF-21 with other serum biomarkers for predicting liver steatosis severity (29). Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.